PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16175949-6 2005 After switching Aza to methotrexate (Mtx) treatment, his symptoms disappeared and CRP concentration returned to normal. Azathioprine 16-19 C-reactive protein Homo sapiens 82-85 15527680-5 2004 Azathioprine and 6-mercaptopurine remain efficient beyond 4 years in patients with relapses and elevated C-reactive protein in spite of this therapy. Azathioprine 0-12 C-reactive protein Homo sapiens 105-123 15097439-0 2004 Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. Azathioprine 116-128 C-reactive protein Homo sapiens 46-64 15097439-5 2004 The authors observed an unexplained discordance between ESR and CRP in children with asymptomatic IBD who were being treated with AZA or 6-MP. Azathioprine 130-133 C-reactive protein Homo sapiens 64-67 15097439-6 2004 OBJECTIVE: To characterize children with IBD in remission treated with 6-MP or AZA who have persistently elevated ESR but normal CRP. Azathioprine 79-82 C-reactive protein Homo sapiens 129-132 15097439-12 2004 Duration of AZA or 6-MP therapy was greater in the 11 children with asymptomatic disease and discordant ESR and CRP than in those with or without symptoms and with concordant ESR and CRP (58.1 +/- 16.4 months v 36.6 +/- 24.1 months, P = 0.0043). Azathioprine 12-15 C-reactive protein Homo sapiens 112-115 15097439-12 2004 Duration of AZA or 6-MP therapy was greater in the 11 children with asymptomatic disease and discordant ESR and CRP than in those with or without symptoms and with concordant ESR and CRP (58.1 +/- 16.4 months v 36.6 +/- 24.1 months, P = 0.0043). Azathioprine 12-15 C-reactive protein Homo sapiens 183-186 15097439-16 2004 CONCLUSIONS: The results suggest that among children treated with AZA or 6-MP, CRP may be a more reliable indirect indicator of inflammation than ESR. Azathioprine 66-69 C-reactive protein Homo sapiens 79-82 15097439-17 2004 This report alerts clinicians that some children taking AZA or 6-MP may have persistent elevation of the ESR with a normal CRP and have no clinical evidence of active disease. Azathioprine 56-59 C-reactive protein Homo sapiens 123-126 14734128-11 2004 CONCLUSIONS: Changing immunosuppression from a standard AZA-based regimen to MMF resulted in a decrease in systemic inflammatory activity as indicated by levels of high-sensitive CRP. Azathioprine 56-59 C-reactive protein Homo sapiens 179-182 3285537-3 1988 Serum CRP concentration rose in response to operation in virtually all patients, regardless of immunosuppressive regimen, from mean baselines of 5.9 +/- 2.7 mcg/ml (AZA) and 6.8 +/- 6.5 mcg/ml (CsA) to mean peak levels of 43.8 +/- 33.4 mcg/ml and 65.1 +/- 39.5 mcg/ml, respectively. Azathioprine 165-168 C-reactive protein Homo sapiens 6-9 11383598-8 2001 Under azathioprine, gastroduodenal and intestinal permeability, CDAI, and C-reactive protein decreased. Azathioprine 6-18 C-reactive protein Homo sapiens 74-92 8549944-8 1995 There were significantly greater decreases over the trial period in the median erythrocyte sedimentation rate, C reactive protein, and leucocyte count in the azathioprine group. Azathioprine 158-170 C-reactive protein Homo sapiens 111-129 7685225-4 1993 The DMARDs such as gold salts, D-penicillamine, sulphasalazine and azathioprine have been shown to reduce serum CRP concentrations significantly in patients with RA. Azathioprine 67-79 C-reactive protein Homo sapiens 112-115 3285537-1 1988 Acute or persistent elevations in serum C-reactive protein (CRP) concentration have been shown to be of value in diagnosing acute rejection episodes in azathioprine (AZA)-treated renal transplant recipients. Azathioprine 152-164 C-reactive protein Homo sapiens 40-58 3285537-1 1988 Acute or persistent elevations in serum C-reactive protein (CRP) concentration have been shown to be of value in diagnosing acute rejection episodes in azathioprine (AZA)-treated renal transplant recipients. Azathioprine 152-164 C-reactive protein Homo sapiens 60-63 3285537-1 1988 Acute or persistent elevations in serum C-reactive protein (CRP) concentration have been shown to be of value in diagnosing acute rejection episodes in azathioprine (AZA)-treated renal transplant recipients. Azathioprine 166-169 C-reactive protein Homo sapiens 40-58 3285537-1 1988 Acute or persistent elevations in serum C-reactive protein (CRP) concentration have been shown to be of value in diagnosing acute rejection episodes in azathioprine (AZA)-treated renal transplant recipients. Azathioprine 166-169 C-reactive protein Homo sapiens 60-63 8097536-4 1993 In a trial comparing methotrexate with azathioprine significant differences could be found in favor of methotrexate by the variables of pain, DAS, ESR, C-reactive protein, hemoglobin and thrombocytes; not by Ritchie score, number of tender joints and number of swollen joints. Azathioprine 39-51 C-reactive protein Homo sapiens 152-170 35584442-0 2022 C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study. Azathioprine 112-124 C-reactive protein Homo sapiens 0-18 35584442-1 2022 OBJECTIVE: To examine serum C-reactive protein levels and the prevalence of leukopenia in patients with Crohn"s disease or ulcerative colitis undergoing treatment with azathioprine and/or mesalazine. Azathioprine 168-180 C-reactive protein Homo sapiens 28-46 3285537-4 1988 CRP rose during 76% of acute rejection episodes in AZA patients by a mean of 29.7 +/- 37.4 mcg/ml. Azathioprine 51-54 C-reactive protein Homo sapiens 0-3 29212102-1 2017 A 24-year old woman with a history of Crohn"s disease developed bloody diarrhea and multiple abdominal abscesses, daily fever, leukocytosis, and elevated CRP several months after her immunosuppressive therapy with azathioprine was stopped. Azathioprine 214-226 C-reactive protein Homo sapiens 154-157 33987044-11 2021 He was started on azathioprine and prednisone and showed a positive response, indicated by a decreasing erythrocyte sedimentation rate and C-reactive protein. Azathioprine 18-30 C-reactive protein Homo sapiens 139-157 33240902-12 2020 Multivariate analysis revealed C-reactive protein >10 mg/L at disease relapse on AZA monotherapy [adjusted hazard ratio (HR), 4.72; 95% CI, 1.19-18.75, P = 0.027] and 6-thioguanine nucleotides level >=235 pmol/8 x 108 erythrocytes at AZA monotherapy (adjusted HR, 5.32; 95% CI, 1.40-20.14, P = 0.014) were associated with disease relapse on combination therapy. Azathioprine 81-84 C-reactive protein Homo sapiens 31-49 33240902-12 2020 Multivariate analysis revealed C-reactive protein >10 mg/L at disease relapse on AZA monotherapy [adjusted hazard ratio (HR), 4.72; 95% CI, 1.19-18.75, P = 0.027] and 6-thioguanine nucleotides level >=235 pmol/8 x 108 erythrocytes at AZA monotherapy (adjusted HR, 5.32; 95% CI, 1.40-20.14, P = 0.014) were associated with disease relapse on combination therapy. Azathioprine 234-237 C-reactive protein Homo sapiens 31-49 25636121-10 2015 Elevated CRP at diagnosis was associated with a higher risk of progression to surgery in patients with CD (P < 0.0001) and the need for azathioprine in the overall PIBD cohort (P = 0.002). Azathioprine 139-151 C-reactive protein Homo sapiens 9-12 22081542-8 2012 Elevated hs-CRP at diagnosis was associated with disease location (P = 0.002), noninflammatory disease behavior (P = 0.058), and a subsequent need for later azathioprine/biological therapy (P < 0.001 and P = 0.024), respectively. Azathioprine 157-169 C-reactive protein Homo sapiens 12-15 23974954-10 2014 CONCLUSIONS: Half the patients under azathioprine and/or infliximab in clinical remission have endoscopic and/or CRP evidence of residual active CD, whereas other patients with endoscopic and CRP normalisation have persistent clinical symptoms. Azathioprine 37-49 C-reactive protein Homo sapiens 113-116 23974954-10 2014 CONCLUSIONS: Half the patients under azathioprine and/or infliximab in clinical remission have endoscopic and/or CRP evidence of residual active CD, whereas other patients with endoscopic and CRP normalisation have persistent clinical symptoms. Azathioprine 37-49 C-reactive protein Homo sapiens 192-195 21677600-6 2011 The levels of C-reactive protein and vascular cell adhesion molecule-1 declined significantly with AZA+everolimus, whereas MMF+everolimus patients demonstrated a significant increase in levels of C-reactive protein, vascular cell adhesion molecule-1, and von Willebrand factor. Azathioprine 99-102 C-reactive protein Homo sapiens 14-32 19381059-8 2009 With the treatment with antibiotics, 5-aminosalicylic acid, steroid, and azathioprine, as a whole, decreasing pattern and intermittent fine coordinated fluctuation of the levels of amylase and lipase along with the decrease of Crohn"s disease activity index (CDAI) and the CRP levels were observed. Azathioprine 73-85 C-reactive protein Homo sapiens 273-276